Priorities for Improving Outcomes for Non-Malignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network

Non-malignant blood diseases such as bone marrow failure disorders, immune dysregulation disorders, and hemoglobinopathies often lead to shortened lifespans and poor quality of life. Many of these diseases can be cured with allogeneic hematopoietic cell transplantation (HCT), but patients are often not offered the procedure because of perceived insufficient efficacy and/or excess toxicity. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN), which is funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), is uniquely positioned to strategically prioritize and address these concerns.

Source: Biology of Blood and Marrow Transplantation - February 4, 2020 Category: Hematology Authors: John E. Levine, Joseph H. Antin, Carl E. Allen, Lauri M. Burroughs, Kenneth R. Cooke, Steven Devine, Helen Heslop, Ryotaro Nakamura, Julie An Talano, Gregory Yanik, Nancy DiFronzo Source Type: research